Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga
about
Standards of medical care in diabetes--2012Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunitiesAnti-atherogenic effects of fibrates in type 2 diabetesStatins research unfinished saga: desirability versus feasibilityComparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS studyFenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]Quality of life after acute myocardial infarction: a comparison of diabetic versus non-diabetic acute myocardial infarction patients in Quebec acute care hospitalsPreventing macrovascular disease in patients with type 2 diabetes mellitusCardiovascular disease in type 2 diabetes: challenge for treatment and preventionManagement of diabetic nephropathyCardiovascular disease: much more aggressive in patients with type 2 diabetesDrugs for cardiovascular risk reduction in the diabetic patientGuidelines for improving the care of the older person with diabetes mellitusCompliance with clinical practice guidelines for type 2 diabetes in rural patients: treatment gaps and opportunities for improvementReducing cardiovascular disease risk in patients with diabetes: a message from the National Diabetes Education ProgramLipid lowering targets are easier to attain than those for treatment of hypertension in type 2 diabetesAll-cause mortality in patients with type 2 diabetes in association with achieved hemoglobin A(1c), systolic blood pressure, and low-density lipoprotein cholesterol levels3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipaseStandards of medical care in diabetes--2013Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes.The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.Modifications of coronary risk factors.Cardiometabolic risk management in type 2 diabetes and obesity.Diabetic cardiovascular disease: getting to the heart of the matter.Screening for Type 2 diabetes--should it be now?Diabetes: statins, fibrates, or both?Two-week treatment with pravastatin improves ventriculo-vascular haemodynamic interactions in young men with type 1 diabetes.Standards of medical care in diabetes--2010.Management of Elevated Cholesterol in the primary prevention Group of Adult Japanese (MEGA) Study assists the view that a fasting plasma glucose level ≥100 mg/dL increases cardiovascular risk.Should all diabetic patients be treated with a statin?Effects of walnut oil on lipid profiles in hyperlipidemic type 2 diabetic patients: a randomized, double-blind, placebo-controlled trialImportance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.Process of care compliance is associated with fewer diabetes complicationsDiabetes as "Coronary Artery Disease Risk Equivalent": A Historical PerspectiveReassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients--a systematic review and meta-analysis.Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in FinlandEffective diabetes care: a need for realistic targets.Evidence-based therapy for type 2 diabetes. The best and worst of times.Diabetes mellitus and coronary heart disease--from prevention to intervention: Part I.Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
P2860
Q24632533-B00A64DA-3374-4F29-9652-8C3AACDEC18DQ24793111-CDDDB4E1-DF91-484C-A0C3-A59F746C2E74Q24806921-6DF20FB2-AEE3-478E-BA47-41D42FBB2097Q24811267-2DD96A1D-5087-4452-84A5-347125339628Q24814804-F0F4D52F-D6FF-432F-A1BF-18F4FEA74223Q24815913-72347314-741E-4FFE-9896-EE2BE1641B76Q25257680-D806D817-4E46-4904-A7FA-C4F3C871F0FDQ28166817-E375C665-3C35-45C1-9480-3A9719C5F13CQ28181344-FC1A3EC1-FDA3-467A-A197-14CAC51C1668Q28184526-E35E3F10-ADD3-4441-B2FB-450A98208568Q28192271-138F19BB-66DD-41ED-834B-89B3C657EC75Q28195413-ABBAC119-767C-4A9F-B7E8-4C815663C3F9Q28195662-70BEAA86-E3A6-4B63-8D6B-A2265A069992Q28195948-463A2FFB-938C-40A2-A3FE-0449FF661780Q28201111-72A1B2FC-550A-4FAB-8C83-0CAD10D7E775Q28219212-CFEE8113-869A-4866-9BDA-10120DE8B75AQ28544402-81737601-C779-437D-88F9-AD482B336E18Q28572175-6E7A0375-2422-43DA-9D5E-B85A9930CEACQ29620309-1D70A81D-140E-4B81-AAE4-DF9204B17011Q30310670-7EA8B763-03A2-4A30-BD87-D044BCED7CD8Q30380628-9DAA210E-AB65-43C2-84AB-13828589AEBDQ30439801-58BB540C-4D83-4DCA-88F5-7F0368D414A3Q30446865-52252171-5BDE-47BB-A498-30C58A301717Q30451529-AD97E0C8-3FA4-4F18-9E53-18428E46033CQ30911757-38A89FFA-C804-42EF-8937-C0554AAC525CQ31729104-E088DC73-5CEF-4C9E-A4C2-26EFC139D64AQ33283202-22163302-76A3-473B-935D-BFFE1C66AAF9Q33554238-B6E4ACFB-7C8D-4023-A90A-17D298FAA9B5Q33603564-7E02248E-C9B9-4CAA-9F71-A0659C2C4981Q33610801-8535CC3E-94D5-406D-AA78-52326263AE4EQ33701908-60571C12-377E-4482-B3AF-8638FAB8A0B4Q33706621-EF11EC30-D16C-46A0-B4A0-AB92807DFD59Q33711157-46522B02-4264-482E-89BE-B0FCBB17FFD5Q33737951-6C2CE353-509F-44BC-A096-E93074E57D4FQ33776201-35E561E6-5ED1-49F8-A519-9609CB0F1845Q33795544-C938262D-6460-42E9-B244-FEDC4780B64DQ33811016-C6F29CAC-75D0-4A5F-84CF-5066143AF777Q33938385-FE0A088D-AF31-4E33-80E7-F0F0406E1C01Q33983641-952EBD45-BAE8-429B-90AD-B143DDB57B63Q34030905-41425910-4019-4F8D-BF82-6A867B39C53B
P2860
Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Cardiovascular events and thei ...... ARE) trial. The Care Investiga
@en
Cardiovascular events and thei ...... olesterol and recurrent events
@nl
type
label
Cardiovascular events and thei ...... ARE) trial. The Care Investiga
@en
Cardiovascular events and thei ...... olesterol and recurrent events
@nl
prefLabel
Cardiovascular events and thei ...... ARE) trial. The Care Investiga
@en
Cardiovascular events and thei ...... olesterol and recurrent events
@nl
P2093
P921
P1433
P1476
Cardiovascular events and thei ...... ARE) trial. The Care Investiga
@en
P2093
Goldberg RB
Mellies MJ
Pfeffer MA
P304
P356
10.1161/01.CIR.98.23.2513
P407
P577
1998-12-01T00:00:00Z